Severe or blood glucose confirmed symptomatic hypoglycemia (glucose of 56 mg/dL or less) was not reported in any of the patients receiving semaglutide monotherapy compared to 1.6% of patients receiving placebo
No human study has tested these combinations
It: Does not affect liver enzymes Has no renal toxicity Does not cause stimulant effects Does not disrupt appetite or hormones Is non-habit forming That said, always consult a qualified healthcare provider before starting any new peptide protocol
Maruvada P, Stover PJ, Mason JB, Bailey RL, Davis CD, Field MS, Finnell RH, Garza C, Green R, Gueant JL et al
Martin Dow is committed to providing safe and effective solutions for various health concerns
Blood 2008;112: 2214-21 3